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We performed a molecular epidemiologic survey 
of mutations associated with drug-resistance genes in 
Plasmodium falciparum in northeastern Myanmar. In this 
region, 3 highly mutated drug-resistance haplotypes and 
1 associated with decreased quinine susceptibility were 
prevalent, which suggests that parasites may be resistant 
to multiple commonly used antimalarial drugs.
M
alaria is a major impediment to socioeconomic 
development in the Greater Mekong Subregion 
(GMS) of Southeast Asia (1). Malaria distribution in the 
GMS is extremely uneven, with areas of high endemicity 
in some countries and along international borders. In 
Myanmar, malaria is particularly problematic; more than 
half of malaria cases and approximately three fourths of 
malaria-related deaths in the GMS during 2007 occurred 
in Myanmar. The GMS has been the breeding ground of 
multidrug-resistant Plasmodium falciparum, and resistance 
to chloroquine and antifolates arose there and spread to 
Africa (2,3). In particular, recent detection of reduced 
artemisinin susceptibility at the Thailand–Cambodia 
border is a major concern (4). As a result, drug resistance 
has been monitored extensively in this region. In contrast, 
information about resistance to antimalarial drugs in 
Myanmar is exceptionally scarce. Accordingly, as our 
initial step toward a comprehensive antimalarial drug study 
in Myanmar, we performed a molecular survey of drug 
resistance in the northeastern region of this country.
The Study
We screened by microscopy 4,980 patients with 
febrile illness who sought care at a malaria clinic in 
Kachin State, northeastern Myanmar, during 2007–2009; 
a total of 27.9% had malaria infections. P. falciparum, P. 
vivax, and mixed species infections accounted for 56.7%, 
41.1%, and 2.2% of malaria cases, respectively. Finger-
prick blood samples were obtained from 260 patients with 
uncomplicated P. falciparum infection who had not used 
antimalarial drugs during the previous 2 weeks. Parasite 
DNA was extracted from ﬁ  lter papers and genotyped at 
3 polymorphic genes, which detected 54.6% of samples 
containing mixed-strain infections (5). Of the 118 samples 
with monoclonal infection, 117 samples were successfully 
genotyped by PCR and sequencing at 5 known and putative 
drug-resistance genes (online Technical Appendix Table, 
www.cdc.gov/eid/content/17/3/498-Techapp.pdf), some of 
which have been widely used for resistance surveillance 
and as predictors of clinical efﬁ  cacy of antimalarial drugs.
Sequencing of 2 fragments in the P. falciparum 
chloroquine resistance transporter (pfcrt) gene covering 
single nucleotide polymorphisms (SNPs) at codons 72–76 
and 220, respectively (6), showed that the major chloroquine 
resistance determinant K76T mutation has reached ﬁ  xation 
in the parasite population (Figure 1). All parasites had 
sequence CVIET at positions 72–76, compared with the 
wild-type sequence SVMNK. In addition, the A220S 
mutation associated with chloroquine resistance was 
predominant (99.1%).
Sequencing of 2 P. falciparum multidrug resistance 
1 (pfmdr1) fragments as described (5) detected only the 
N86Y, Y184F, and N1042D mutations making up 5 
haplotypes (Figure 2). The overall haplotype prevalence 
differed signiﬁ  cantly among the years (p<0.001, χ2 = 31.39, 
df = 8).The prevalence of wild-type haplotype was 59.0%. 
Among the 3 mutant codons, only Y184F reached a 
relatively high frequency (35.9%). One sample contained 
the double mutations 184F/1042D. Analysis of pfmdr1 
copy number from monoclonal infections by real-time PCR 
with 3D7 and Dd2 strains as negative and positive controls, 
respectively (6), detected no pfmdr1 ampliﬁ  cation.
Sequencing of the dihydrofolate reductase (pfdhfr) and 
dihydropoteroate synthase (pfdhps) genes (online Technical 
Appendix Table) detected 4 SNPs in pfdhfr associated 
with pyrimethamine resistance (N51I, C59R, S108N, and 
I164L) and 4 SNPs in pfdhps associated with sulfadoxine 
resistance (S436A, A437G, K540E/N, and A581G) (Table 
1). The overall haplotype prevalence of the 2 genes differed 
signiﬁ   cantly between the years (p<0.0001, χ2 = 76.49, 
df = 28). Of the 5 pfdhfr haplotypes, wild-type NCSI was 
observed only in 1 sample in 2007; the remaining samples 
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contained at least double mutations 59R/108N. Two triple-
mutation haplotypes (NRNL and IRNI, mutations in 
boldface) were detected with NRNL being more frequent 
than  IRNI in each year. Overall, quadruple mutations 
(IRNL) were found in >50% of the samples. In addition, 
frequency of triple and quadruple mutations increased 
gradually from 2007 to 2009. We found all 5 haplotypes 
in 2007 but only triple and quadruple mutations in 2009. 
In  pfdhps, 10 haplotypes were found, and 437G and 
540E/N mutations were highly prevalent: 98.3 and 96.6%, 
respectively (Table 1). Similarly, the wild-type pfdhps 
haplotype SGKA was found in only 2 samples. AGEA was 
the most common haplotype in each year and reached an 
overall frequency of 48.7%. Quadruple mutations (AGEG) 
were found only in 2008 and 2009.
Molecular analysis of drug-resistance markers in 
monoclonal infections enabled us to obtain multilocus 
genotypes of the parasites. Genotyping each of the 117 
parasite isolates at 16 drug resistance–related codons in 
the  pfcrt,  pfmdr1,  pfdhfr, and pfdhps genes showed 41 
haplotypes (Figure 1). Among these haplotypes, parasites 
containing >10 mutated codons accounted for 93.2% of the 
samples.
Polymorphisms in the minisatellite ms4760 of P. 
falciparum  Na+/H+ exchanger (pfnhe1) are associated 
with quinine sensitivity (5,7–10). Sequencing of the 
pfnhe1 fragment containing the ms4760 minisatellite from 
79 monoclonal infections showed 10 haplotypes, with 
haplotype 7 the most predominant (54.4%) (Table 2). 
More than 64% of samples tested contained >3 copies of 
the DNNND repeat (Rep1); 76% contained 1 copy of the 
NHNDNHNNDDD repeat (Rep2). Accordingly, >60% of 
parasite isolates had a Rep1:Rep2 ratio of >3:1.
Conclusions
In Myanmar, high-level resistance to chloroquine 
and pyrimethamine–sulfadoxine was reported more than 
a decade ago (11–13). Our molecular survey showed that 
the major chloroquine resistance allele CVIET has reached 
ﬁ  xation, and triple and quadruple mutations in pfdhfr and 
pfdhps were highly prevalent in this region. These ﬁ  ndings 
strongly suggest that a large proportion of parasites might 
show clinical resistance to chloroquine and antifolate 
drugs. Although chloroquine has been withdrawn from 
treating P. falciparum malaria for decades in some regions, 
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Figure 1. Multilocus genotypes in Plasmodium falciparum isolates, 
Kachin State, northeastern Myanmar, 2007–2009. A total of 
41 haplotypes were identiﬁ   ed from 117 parasite isolates. Wild-
type and mutated amino acids are shown in white and black, 
respectively. Prevalence (%) of each multilocus genotype in each 
year is indicated in the right columns.
Figure 2. Annual prevalence of Plasmodium falciparum dihydrofolate 
reductase haplotypes among clinical samples collected from 
Kachin State, northeast Myanmar, 2007–2009. The x-axis shows 
the 5 haplotypes (the amino acids at positions 86, 184, and 1042 
with mutated amino acids in boldface). The χ2 test was performed 
to compare prevalence of 2 major haplotypes between years. For 
each haplotype, NS denotes no signiﬁ   cant difference (p>0.05) 
between years; asterisk (*) denotes signiﬁ  cant difference (p<0.05) 
between years.the pfcrt resistance alleles showed no sign of abating (6). 
Furthermore, despite adoption of artemisinin combination 
therapy in 2002, the frequency of highly mutated pfdhfr 
and pfdhps haplotypes appeared to have increased during 
this study, which suggested that artemisinin combination 
therapy might not have retarded the spread of antifolate-
resistant parasites. This situation differs from that in the 
western Myanmar border area but is similar to that in 
Thailand and Cambodia, where highly mutated pfdhfr and 
pfdhps genotypes also were common (14,15).
Mutations in pfmdr1 are associated with resistance 
to several antimalarial drugs including chloroquine, 
meﬂ   oquine, and quinine and increased pfmdr1 copy 
number is responsible for meﬂ   oquine resistance. We 
found that ≈60% of the parasites contained the wild-type 
pfmdr1 allele, similar to some parasites from the western 
Myanmar border area (15). No pfmdr1 ampliﬁ  cation 
was detected, suggesting that parasites from this region 
might be meﬂ  oquine sensitive, consistent with the fact 
that meﬂ  oquine has not been deployed here. In contrast, 
in vitro meﬂ  oquine resistance was observed in southeast 
Myanmar bordering Thailand (13), possibly because of 
the extensive use of meﬂ  oquine in Thailand for the past 
2 decades.
Although the validity of pfnhe1 minisatellite 
polymorphism for predicting quinine resistance remains 
uncertain and may depend on the parasites’ origins (7–9), 
we detected signiﬁ  cant association of decreased quinine 
susceptibility with increased DNNND repeat copies (5). 
We have provided further evidence on the high prevalence 
of parasites with increased DNNND repeats in pfnhe1, 
which suggests that some parasite strains might show 
reduced sensitivity to quinine.
Overall, our molecular survey of antimalarial drug 
resistance in P. falciparum showed high frequency of 
multidrug-resistant haplotypes in northeastern Myanmar. 
Moreover, parasites in this region had unique multilocus 
genotypes that differed markedly from those in other areas 
of the GMS. These ﬁ  ndings suggest that coordinated efforts 
are necessary to thwart the spread of resistant strains across 
larger geographic regions. Our molecular study showed 
only the genotypes of the drug resistance genes; further in 
vitro and in vivo studies are required to corroborate these 
ﬁ  ndings.
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Table 1. Prevalence of point mutation haplotypes in pfdhfr and pfdhps in clinical samples from Kachin State, northeast Myanmar, 
2007–2009* 
Gene Haplotype  Codon† 
Haplotype prevalence,‡ % 
2007, n = 41  2008, n = 40  2009, n = 36 
Pfdhfr (51, 59, 108, 164)  Wild-type  NCSI  2.4 – –
Double mutations  NRNI 9.8 5.0 –
Triple mutations  NRNL 31.7
a 25.0
b 36.1
a
IRNI 14.6
a 7.5
b 16.7
a
Quadruple mutations  IRNL 41.5
a 62.5
b 47.2
a
Pfdhps (436, 437, 540, 581)  Wild-type  SAKA 2.4 – 2.8
Single mutation  SGKA – 2.5 2.8
Double mutations  SGEA9 . 8 2 . 5 –
SGNA 2.4 – –
Triple mutations  SGEG 26.8
a 35.0
b 19.4
c
SGNG 2.4 2.5 –
AGEA 48.8
a 45.0
a 52.8
a
AGNA 7.3 – 8.3
Quadruple mutations  AGEG – 10.0 11.1
AGNG – 2.5 2.8
*Pfdhfr, Plasmodium falciparum dihydrofolate reductase; Pfdhps, P. falciparum dihydropoteroate synthase; –, no such haplotype detected. 
†Codons in boldface indicate mutated amino acids. 
‡Ȥ
2 test was performed with all data points of the 2 genes, which showed that overall haplotype prevalence differed significantly between the years (Ȥ
2
test, p<0.0001, Ȥ
2 = 76.49, df = 28). Major dhfr and dhps haplotypes were individually compared. For each haplotype (in the same row), the labeling by 
different letters denotes significant difference between the years (Ȥ
2 test, p<0.05). 
Table 2. Prevalence of the pfnhe1 minisatellite ms4760 
haplotypes in the clinical samples from Kachin State, northeast 
Myanmar, 2007–2009* 
Haplotype†  No. rep 1  No. rep 2 
Haplotype 
frequency, % 
1 2 2 12.7
31 2 5 . 1
54 1 3 . 8
6 2 1 13.9
7 3 1 54.4
93 2 3 . 8
14 3 1 1.3
18 2 2 2.5
34 4 1 1.3
35 1 1 1.3
*Pfnhe1, Plasmodium falciparum Na
+/H
+ exchanger. 
†Numbers refer to the haplotype list of Meng et al. (5).Multidrug-Resistant P. falciparum, Myanmar
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